CARLSBAD, Calif., Sept. 25 /PRNewswire/ -- AviaraDx, Inc., a molecular cancer profiling company enabling personalized medicine in oncology, announced today the publication of a case study, in the September 7th issue of the New England Journal of Medicine, that utilized an assay based upon the company’s Molecular Cancer Identification (MCID) technology for the diagnosis of cancer of unknown primary. The case study was based on a CUP assay developed by a European licensee of AviaraDx.
“We are pleased NEJM has chosen to publish this case study, which provides an example of the benefits that the AviaraDx molecular profiling technology brings to the diagnostic evaluation of these often difficult cases,” said Mark Erlander, Ph.D., Chief Scientific Officer of AviaraDx, Inc. “Correctly identifying the primary tumor origin in CUP patients provides the clinician with options for improved therapy regimens, resulting in better patient prognosis.”
About AviaraDx, Inc.
AviaraDx, Inc., is focused on developing and commercializing molecular diagnostic technologies for personalized medicine in cancer treatment. The company is targeting the oncology market with three first-in-class molecular cancer profiling technologies: Molecular Cancer Identification (MCID), Breast Cancer Profiling (BCP) and Drug Response Profiling (DRP). AviaraDx has licensed its technologies for specific clinical indications to Quest Diagnostics, Laboratory Corporation of America and Agendia BV. The Company anticipates operating its own CLIA certified diagnostic laboratory in early 2007 to complement its current partner offerings.
Contact: Sherri Heffner 760-579-0513
AviaraDx, Inc.
CONTACT: Sherri Heffner of AviaraDx, Inc., +1-760-579-0513
Web site: http://www.aviaradx.com/
